Prometheus' Response to COVID-19
NEW Monitr™ M.C.A.P. for adult Crohn's disease Patients
In March 2020, Prometheus Biosciences launched its Monitr COVID-19 Assistance Program (M.C.A.P.) to support adults Crohn’s disease patients have lost employment and or insurance coverage during the COVID-19 pandemic. In addition to the ongoing burdens that CD patients face with their disease, they are now experiencing new challenges as healthcare providers are being asked to cancel routine procedures like colonoscopies in response to the COVID-19 outbreak.
Through M.C.A.P., Prometheus is providing the Monitr test at no charge for those patients who have lost employment and or insurance coverage during the COVID-19 outbreak. This program will be available to all qualifying patients from March 23, 2020 through June 1, 2020 where Prometheus Biosciences acts as the billing entity. For all other patients, Prometheus’ existing financial assistance programs are still available. In addition, Prometheus is also working on continued, uninterrupted access to their mobile phlebotomy services to facilitate sample collection and mitigate the need for patients to engage in any unnecessary travel. If you have any questions on the MCAP program or how to order the Prometheus Monitr CD test, please contact Prometheus’ client services team at 888-423-5227 or visit http://MonitrCD.com/MCAP.
View the press release here.